ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
